ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015

A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.

Igor Puzanov et al.PubMed ↗Publisher ↗

No numbers read from the abstract.